Pharma Pulse: FDA Expands Pediatric UC Treatment Options, AstraZeneca and Algen Partner in Neurology, and Peli BioThermal Boosts Cold Chain Capabilities

Oct 09, 09:30 AM

Headliner
Share
Subscribe
This episode of Pharma Pulse covers the FDA’s approval of golimumab for pediatric ulcerative colitis, AstraZeneca’s new multi-target neuroscience partnership with Algen, and Peli BioThermal’s acquisition of Evo to strengthen its global cold chain portfolio.
Share
Subscribe
Next
Pharma Pulse: CDC Updates Vaccine Guidance, GLP-1s Linked to Imaging Challenges, and Novo Nordisk Loses Inflation Reduction Act Appeal
Top episodes
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce